Drug Type CAR-T |
Synonyms EBV-CTL-Atara-MSKCC |
Target |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
EBV viremia | Phase 2 | US | 01 Dec 2011 | |
Epstein-Barr virus associated lymphoproliferative disorder | Phase 2 | US | 01 Dec 2011 | |
Epstein-Barr Virus-Related Lymphoma | Phase 2 | US | 01 Dec 2011 |
Phase 2 | 87 | (HCT EBV+ PTLD R/R Rituximab) | aeefrukhqf(rqzyzwinog) = qmcmduvdjt kqutnpnwji (jfvrxclkqe, rynoevtgzp - zxuickwegd) View more | - | 21 Oct 2022 | ||
EBV-specific T cells (EBV-CTLs) (SOT EBV+ PTLD R/R Rituximab) | aeefrukhqf(rqzyzwinog) = hcmyzkupoh kqutnpnwji (jfvrxclkqe, kprrhkvcxi - sfyzlwzvyp) View more |